TAMPA, Fla.--(BUSINESS WIRE)--Aug. 28, 2006--Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI), has signed an amendment to its license with the Mayo Foundation for Medical Research and Education (Mayo Clinic). This amendment grants Accentia an exclusive worldwide license to all non-prescription (over-the-counter - OTC) products that are intended to treat symptoms associated with chronic sinusitis (CS) by suppressing non-invasive (so-called “saprophytic”) fungi in the mucus of patients. The amendment also grants Accentia the right to proceed with commercialization of a first product.
